Výsledky vyhledávání - "Lyubov Efros"

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®

Autor: Thierry Sornasse, Stephen Hartman, Lyubov Efros, Vladimir Vexler, Bishu Ganguly, Archana B. Thakur, Joanna M. Xiong, Paul R. Hinton, Balaji Balasa, James P Sheridan, Randy R. Robinson, Brian Schmidt

Publikováno v: mAbs

The CD25-binding antibody daclizumab high-yield process (DAC HYP) is an interleukin (IL)-2 signal modulating antibody that shares primary amino acid sequence and CD25 binding affinity with Zenapax®, a distinct form of daclizumab, which was approved

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dbe63bfbb3319e44289c735f69665f3
https://doi.org/10.1080/19420862.2016.1207031

Zobrazit plný text záznamu

Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis

Autor: James Sheridan, MT Tang, M McClellan, Lyubov Efros, Vladimir Vexler, D Shi, Ying Zhang, Bibi Bielekova

Publikováno v: Multiple Sclerosis Journal. 20:156-164

Daclizumab is a humanized monoclonal antibody that prevents interleukin-2 (IL-2) binding to CD25, blocking IL-2 signaling by cells that require high-affinity IL-2 receptors to mediate IL-2 signaling. The phase 2a CHOICE study evaluating daclizumab as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcd130cb8a1fd57813e597420d8e55fe
https://doi.org/10.1177/1352458513494488

Zobrazit plný text záznamu

Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

Autor: Jia Shi, Jeffrey Harris, Katherine Riester, Ying Zhang, Lyubov Efros, Vladimir Vexler, Jacob Elkins, Meina T Tang, James Sheridan

Publikováno v: Multiple Sclerosis Journal. 17:1441-1448

Objective: The objective of this study was to evaluate whether interleukin-2 (IL-2) receptor expression on CD56bright natural killer (NK) cells predicted CD56bright NK cell expansion and therapeutic response to daclizumab (DAC) in multiple sclerosis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510c7feabefd172422e8e352b97dd85c
https://doi.org/10.1177/1352458511414755

Zobrazit plný text záznamu

HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke

Autor: Judy Huang, Lyubov Efros, J. Mocco, Sulli Popilskis, Corine Klingbeil, William C. Hall, William J. Mack, E. Sander Connolly, Tanvir F. Choudhri, Yuan Zhang, Vladimir Vexler, David J. Pinsky, Elisabeth Harfeldt

Publikováno v: Circulation research. 91(10)

Although inhibiting interaction of β2integrins with cognate immunoglobulin class adhesion receptor ligands is an effective neuroprotective strategy in small mammal models of stroke, the strategy has failed in human trials. A completely different ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::731f889de3b31ca5c84ca7c4eb0315c7
https://pubmed.ncbi.nlm.nih.gov/12433835

Zobrazit plný text záznamu

F.84. Daclizumab Rapidly Decreases CD25 Expression On Activated CD4+ Cells In Vitro Without Cell Killing and Through a Fc Receptor- and Monocyte-Dependent Mechanism

Autor: Ying Zhang, Vladimir Vexler, Lyubov Efros, James Sheridan, Randall Schreck

Publikováno v: Clinical Immunology. 119:S80-S81

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::87cd36202aecd47c671ce0f262cfed86
https://doi.org/10.1016/j.clim.2006.04.124

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání